OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Clinical trials for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) explained in plain language.
Never miss a new study
Get alerted when new OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) trials appear
Sign up with your email to follow new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New heart drug aficamten challenges standard Beta-Blocker in major trial
Disease control CompletedThis study tested a new drug called aficamten against the standard medicine metoprolol in 175 adults with a heart condition that makes the heart muscle thick and blocks blood flow. The goal was to see which drug better improves exercise ability and symptoms like shortness of brea…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Heart drug mavacamten shows promise in Real-World study
Disease control CompletedThis study looked at 222 adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers compared those who took mavacamten (Camzyos) with those on standard therapy, measuring changes in heart function and sympto…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill aims to help heart patients breathe easier and move more
Disease control CompletedThis Phase 3 trial tested a daily pill called aficamten in 282 adults with a type of thickened heart muscle that blocks blood flow and causes symptoms like shortness of breath and chest pain. Participants received either aficamten or a placebo for 24 weeks. The main goal was to s…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Real-World data: mavacamten shows promise for heart condition in canadian patients
Disease control CompletedThis study looked at 115 Canadian adults with obstructive hypertrophic cardiomyopathy (oHCM) who started taking mavacamten as part of routine care. Researchers reviewed patient charts to see if the drug improved heart function and symptoms. The goal was to understand how mavacamt…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Real-World data shows Mavacamten's impact on heart condition
Disease control CompletedThis study looked at 163 patients with obstructive hypertrophic cardiomyopathy who were prescribed mavacamten at a single US hospital. Researchers collected information on symptoms, heart function, and patient characteristics from medical records. The goal was to see how the drug…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 15:36 UTC